Pfizer Inc. $PFE Holdings Decreased by Focused Wealth Management Inc

Key Points

• Focused Wealth Management Inc. reduced its Pfizer stake by 27.4% in the first quarter, selling 43,459 shares and leaving it with 115,258 shares valued at about $3.24 million.
• Pfizer reported better-than-expected quarterly results, posting $0.75 EPS versus the $0.72 estimate and revenue of $14.45 billion, which was also above forecasts. The company also reaffirmed FY 2026 EPS guidance of $2.80 to $3.00.
• The stock continues to offer a high dividend yield of about 6.9%, but sentiment is mixed as analysts largely rate it a Hold and a recent late-stage lung cancer drug trial missed its main survival goal.

Focused Wealth Management Inc trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 27.4% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 115,258 shares of the biopharmaceutical company's stock after selling 43,459 shares during the period. Focused Wealth Management Inc's holdings in Pfizer were worth $3,236,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Kepler Cheuvreux Suisse SA purchased a new position in shares of Pfizer during the 3rd quarter valued at $16,613,000. Mackenzie Financial Corp raised its holdings in shares of Pfizer by 119.6% during the third quarter. Mackenzie Financial Corp now owns 3,106,644 shares of the biopharmaceutical company's stock worth $79,157,000 after acquiring an additional 1,691,773 shares in the last quarter. Penn Davis Mcfarland Inc. boosted its position in Pfizer by 50.9% during the fourth quarter. Penn Davis Mcfarland Inc. now owns 171,332 shares of the biopharmaceutical company's stock valued at $4,266,000 after purchasing an additional 57,777 shares during the last quarter. Ameriprise Financial Inc. boosted its position in Pfizer by 48.2% during the third quarter. Ameriprise Financial Inc. now owns 18,373,140 shares of the biopharmaceutical company's stock valued at $468,174,000 after purchasing an additional 5,978,927 shares during the last quarter. Finally, Danske Bank A S purchased a new position in Pfizer in the third quarter valued at about $81,298,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Price Performance

Shares of NYSE:PFE opened at $24.75 on Wednesday. The company has a market cap of $141.06 billion, a price-to-earnings ratio of 18.89 and a beta of 0.34. The business has a 50 day moving average price of $26.13 and a 200 day moving average price of $26.33. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. Pfizer Inc. has a twelve month low of $23.11 and a twelve month high of $28.75.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. During the same period in the previous year, the business posted $0.92 EPS. The company's revenue for the quarter was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Research analysts predict that Pfizer Inc. will post 2.99 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, June 12th. Investors of record on Friday, May 8th were given a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. Pfizer's payout ratio is 131.30%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Royal Bank Of Canada raised Pfizer from an "underperform" rating to a "sector perform" rating and set a $25.00 price target for the company in a research note on Tuesday, June 9th. Morgan Stanley boosted their price target on Pfizer from $27.00 to $28.00 and gave the company an "equal weight" rating in a research note on Friday, April 10th. Wolfe Research restated an "underperform" rating and issued a $26.00 price objective on shares of Pfizer in a report on Thursday, May 14th. Weiss Ratings raised shares of Pfizer from a "hold (c-)" rating to a "hold (c)" rating in a research report on Wednesday, May 6th. Finally, Argus upgraded shares of Pfizer from a "hold" rating to a "buy" rating and set a $35.00 target price for the company in a research note on Monday, March 2nd. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Pfizer presently has a consensus rating of "Hold" and an average price target of $28.82.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer is getting credit for longer-term growth optionality in obesity and broader healthcare innovation, with some commentary highlighting its pipeline as an underappreciated driver and its use of AI to improve operations. Pfizer Isn't Expecting to Make Any Big Acquisition in the Next Couple of Years, but It's Planning to Do This Instead
• Positive Sentiment: Several articles point to Pfizer’s dividend yield and its obesity pipeline as reasons some investors remain interested in the stock while waiting for new products to ramp. Forget Novo Nordisk. Pfizer’s Obesity Pipeline Is Coming, and It Pays You 6.8% While You Wait
• Neutral Sentiment: Pfizer said it will host a webcast of its August 4 second-quarter 2026 results call, which is a routine investor update rather than a direct catalyst. Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts
• Neutral Sentiment: Nike named Pfizer finance executive David Denton as its next CFO, which reflects positively on Pfizer’s leadership bench but is not a direct operating update for PFE shares. Nike Names Pfizer's Denton as Next CFO
• Negative Sentiment: Pfizer’s experimental lung cancer drug sigvotatug vedotin failed to meet the main overall-survival goal in a late-stage trial versus chemotherapy, a setback that is weighing on sentiment around the stock today. Pfizer's experimental drug misses main goal of lung cancer trial
• Negative Sentiment: While the drug showed benefit in some subgroups, the mixed readout underscores ongoing execution risk in Pfizer’s oncology portfolio, especially for assets tied to its Seagen acquisition. Pfizer (PFE) Lung Cancer Drug Misses Survival Goal In Phase 3 Trial

Pfizer Company Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.